Who published this market news?

TradingView published this market news item.

Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans

Gain Therapeutics announced its cash and cash equivalents are expected to fund operations into the second quarter of 2027.Key Highlights:Original SEC Filing: Gain Therapeutics, Inc. [ GANX ] - 8-K - Jul. 16, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying importan…

Gain Therapeutics announced its cash and cash equivalents are expected to fund operations into the second quarter of 2027.

Key Highlights:

Company expects current cash to fund operations into Q2 2027 based on current operating plans.
Plans include completion of Phase 1b open‑label extension in October 2026.
Initiation of a Phase 2 clinical study is planned for Q3 2026, per the shareholder letter.
Forward‑looking statements caution actual results may differ; see 10‑K and SEC filings for risks.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.